Agenus shared a post on LinkedIn:
“At ESMO GI 26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal cancer without active liver metastases.
The presentation reflects an additional year of follow-up from the 123-patient cohort previously presented at ESMO GI 2025.
Watch below for presentation timing and details.”
To which Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, added:
“Updated long-term follow-up for BOT+BAL at ESMO GI 26!
Expecting to see 3 years of follow-up from the original 123-patient cohort which will provide important insight into the durability of outcomes in MSS metastatic colorectal cancer without active liver metastases. Long-term follow-up matters.
Let’s watch for that exciting ‘Tail of the curve’!”
Other articles about Agenus and Jennifer S. Buell on OncoDaily.